Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
CYTH2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CYTH2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CYTH1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CYTH1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CYP4Z1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CYP4Z1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Spinocerebellar ataxia type 1 Indication Strategy Report 2026: ATXN1, Trials and Deals
21 July 2026
Spinocerebellar ataxia type 1 indication strategy report covering epidemiology, ATXN1 biology, active trials, competition and deal signals using PatSnap MCP...
8 min read
CYP4X1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CYP4X1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CYP46A1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CYP46A1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CYP39A1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CYP39A1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CYP27C1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CYP27C1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CYP26C1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CYP26C1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CYP26B1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CYP26B1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Spinocerebellar ataxia type 3 Indication Strategy Report 2026: ATXN3, Trials and Deals
21 July 2026
Spinocerebellar ataxia type 3 indication strategy report covering epidemiology, ATXN3 biology, active trials, competition and deal signals using PatSnap MCP...
8 min read
CYP20A1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CYP20A1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.